005690.KO Pharmicell
- Market cap
- KRW 522B
- P/E
- -
- P/B
- 3.78x
- ROE
- 30.8%
- Dividend yield
- 0.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 005690.KO undervalued?
Graham numberThe Graham number of Pharmicell cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmicell fundamental analysis
No fundamental analysis for Pharmicell yet.
Pharmicell stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cel…
Full company profilePharmicell financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmicell annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 27.8B | 25.2B | 28.4B | 32.5B | 37.8B | 51.8B | 60.2B | 56.2B | 64.9B | 114B | 151B |
| Gross Profit | 10.2B | 8.07B | 11.8B | 13.0B | 17.8B | 23.7B | 23.8B | 15.5B | 21.3B | 50.7B | 68.9B |
| Operating Income | -1.87B | -4.46B | 260M | 1.96B | 7.23B | 7.86B | 8.87B | 1.30B | 4.66B | 34.3B | 52.6B |
| EBITDA | - | -1.13B | -11.0B | 4.34B | 7.10B | 12.9B | 8.90B | 8.44B | 9.43B | 37.9B | 55.6B |
| Net Income | -677M | -39.2B | -12.7B | 4.35B | 5.24B | 9.45B | 8.26B | 3.58B | 6.33B | 40.3B | 44.2B |
| EPS | - | -671 | -212 | 73 | 87 | 158 | 138 | 60 | 106 | 671 | 736 |
| Balance Sheet | |||||||||||
| Total Assets | 102B | 63.8B | 59.1B | 63.3B | 69.7B | 94.3B | 110B | 92.5B | 99.3B | 157B | 184B |
| Total Liabilities | 7.36B | 7.76B | 11.6B | 11.7B | 12.6B | 30.5B | 33.0B | 12.1B | 12.8B | 33.3B | 40.8B |
| Shareholders' Equity | 94.6B | 56.0B | 47.5B | 51.5B | 57.1B | 63.9B | 76.7B | 80.4B | 86.4B | 124B | 143B |
| Cash & Short-term Investments | 11.9B | 13.0B | 18.6B | 16.7B | 20.9B | 26.2B | 14.4B | 13.7B | 8.26B | 28.9B | 15.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 989M | -2.01B | 3.40B | -75.5M | 8.98B | -5.22B | 7.91B | 11.8B | 3.50B | 41.1B | 29.9B |
| Capital Expenditure | 3.85B | 4.27B | 4.68B | 1.66B | 743M | 4.32B | 19.0B | 6.02B | 4.34B | 7.49B | 15.6B |
| Free Cash Flow | - | -6.28B | -1.27B | -1.74B | 8.24B | -9.54B | -11.0B | 5.79B | -840M | 33.6B | 14.3B |
| Ratios | |||||||||||
| ROE | -0.7% | -70.0% | -26.7% | 8.4% | 9.2% | 14.8% | 10.8% | 4.5% | 7.3% | 32.5% | 30.8% |
| ROA | -0.7% | -61.5% | -21.5% | 6.9% | 7.5% | 10.0% | 7.5% | 3.9% | 6.4% | 25.6% | 24.0% |
| Net Profit Margin | -2.4% | -155.6% | -44.7% | 13.4% | 13.9% | 18.2% | 13.7% | 6.4% | 9.8% | 35.3% | 29.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pharmicell dividends
- Dividend yield
- 0.23%
- Forward dividend
- 50.00 KRW
- Payout ratio
- 3.0%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.20B | 20 | 3.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Dec 19, 2011.
Who owns Pharmicell
- Insiders 9.56%
- Institutions 5.89%
- Public & others 84.55%
- Shares outstanding 60.0M
- Free float 40.8M
Pharmicell company profile
- Company name
- Pharmicell
- Ticker
- 005690.KO
- ISIN
- KR7005690003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Ssangbong Building, Seoul, South Korea
- Phone
- 82 2 3496 0114
- Website
- pharmicell.com
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Pharmicell management
3- Mr. Hyun-Soo KimCEO & Chairman of the Board of Director · born 1964
- Mr. HeeCheol JeongMD, Internal Accounting Manager & Controller · born 1964
- Mr. Gil Su JeongMD, Head of Biomedical Division & Director · born 1976